Research and Markets: Cancer Drugs with Apoptotic Targets in Development - Key Information on 138 Targeted Apoptotic Drugs in Anticancer Development

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/79bf6a/cancer_drugs_with) has announced the addition of the "Cancer Drugs with Apoptotic Targets in Development" report to their offering.

Cancer drugs with apoptotic targets in development, updated July 2010, provides key information on 138 targeted apoptotic drugs in anticancer development by a total of 104 companies. These drugs are directed at the products of one or more of over 40 genes involved in apoptosis (programmed cell death).

Most current cancer therapies, including chemotherapeutic agents, work by inducing apoptosis in cancer cells. However, many cancer cells are resistant or develop resistance to these agents. A promising new direction for drug development involves approaches designed to overcome treatment resistance due to over-expression of anti-apoptotic genes or down regulation of pro-apoptotic genes.

Apoptotic drugs in anticancer development were identified using a wide variety of sources, including Biophoenix's proprietary company database, various online databases, the scientific literature, academic and company websites, company press releases, web-based news searches, industry newsletters, and conference proceedings. Apoptotic anticancer drugs are characterized in terms of their target(s), development status, originator company/licensee, therapy type, mode of action, and indication.

Key Topics Covered:

  • Introduction
  • Gene targets of apoptotic drugs
  • Table 1 Overview of drugs with apoptotic targets in anticancer development
  • TNF family and death receptors as drug targets
  • Table 2 TNF family and death receptor agents in anticancer development
  • Caspases as drug targets
  • Table 3 Caspase agents in anticancer development
  • BCL2 family as drug targets
  • Table 4 BCL2 family agents in anticancer development
  • Inhibitors of apoptosis (IAPs) as drug targets
  • Table 5 IAP and regulator agents in anticancer development
  • Transcription factors as drug targets
  • Table 6 Transcription factor and regulator agents in anticancer development
  • Kinases in the PI3K/AKT pathway as drug targets
  • Table 7 PI3K/AKT kinase agents in anticancer development
  • Histone deacetylases as drug targets
  • Table 8 Histone deacetylase agents in anticancer development
  • Proteasome inhibitors as drug targets
  • Table 9 Proteasome inhibitors in anticancer development
  • Heat shock protein (HSP) inhibitors as drug targets
  • Table 10 Heat shock protein inhibitors in anticancer development

For more information visit http://www.researchandmarkets.com/research/79bf6a/cancer_drugs_with.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716